Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000902664-25-004537
Filing Date
2025-10-23
Accepted
2025-10-23 19:52:36
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 13807
2 SCHEDULE A p25-2248schedulea.htm EX-99 9554
3 JOINT FILING AGREEMENT p25-2248exhibit991.htm EX-99.1 3324
  Complete submission text file 0000902664-25-004537.txt   28591
Mailing Address 100 SUMMIT DR BURLINGTON MA 01803
Business Address 100 SUMMIT DR BURLINGTON MA 01803 781-439-5551
Neuphoria Therapeutics Inc. (Subject) CIK: 0001191070 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: SCHEDULE 13D | Act: 34 | File No.: 005-93208 | Film No.: 251414053
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address D81 CALLE C SUITE 301 PMB 1202 DORADO Puerto Rico 00646
Business Address D81 CALLE C SUITE 301 PMB 1202 DORADO Puerto Rico 00646 703-963-7214
Lynx1 Capital Management LP (Filed by) CIK: 0001910456 (see all company filings)

EIN.: 851134656 | State of Incorp.: DE | Fiscal Year End: 1231
LEI: 5493003YH8Q5SHT17216
Type: SCHEDULE 13D